Skip to main content
  • Main menu
  • User menu
  • Search

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Institution: ISMAI

Search

  • Advanced search
American Society of Nephrology
  • Other
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
Institution: ISMAI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Clinical Research
You have accessRestricted Access

Evidence for Anti-Inflammatory Effects of Exercise in CKD

João L. Viana, George C. Kosmadakis, Emma L. Watson, Alan Bevington, John Feehally, Nicolette C. Bishop and Alice C. Smith
JASN September 2014, 25 (9) 2121-2130; DOI: https://doi.org/10.1681/ASN.2013070702
João L. Viana
*School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George C. Kosmadakis
†John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma L. Watson
‡Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Bevington
‡Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Feehally
†John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolette C. Bishop
*School of Sport, Exercise and Health Sciences, Loughborough University, Leicestershire, United Kingdom;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice C. Smith
†John Walls Renal Unit, Leicester General Hospital, Leicester, United Kingdom; and
‡Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading

Abstract

CKD is associated with a complex state of immune dysfunction characterized by immune depression, predisposing patients to infections, and immune activation, resulting in inflammation that associates with higher risk of cardiovascular disease. Physical exercise may enhance immune function and exert anti-inflammatory effects, but such effects are unclear in CKD. We investigated the separate effects of acute and regular moderate-intensity aerobic exercise on neutrophil degranulation (elastase release), activation of T lymphocytes (CD69 expression) and monocytes (CD86 and HLA-DR expression), and plasma inflammatory markers (IL-6, IL-10, soluble TNF-receptors, and C-reactive protein) in patients with predialysis CKD. A single 30-minute (acute) bout of walking induced a normal pattern of leukocyte mobilization and had no effect on T-lymphocyte and monocyte activation but improved neutrophil responsiveness to a bacterial challenge in the postexercise period. Furthermore, acute exercise induced a systemic anti-inflammatory environment, evidenced by a marked increase in plasma IL-10 levels (peaked at 1 hour postexercise), that was most likely mediated by increased plasma IL-6 levels (peaked immediately postexercise). Six months of regular walking exercise (30 min/d for 5 times/wk) exerted anti-inflammatory effects (reduction in the ratio of plasma IL-6 to IL-10 levels) and a downregulation of T-lymphocyte and monocyte activation, but it had no effect on circulating immune cell numbers or neutrophil degranulation responses. Renal function, proteinuria, and BP were also unaffected. These findings provide compelling evidence that walking exercise is safe with regard to immune and inflammatory responses and has the potential to be an effective anti-inflammatory therapy in predialysis CKD.

CKD is associated with profound alterations in innate and adaptive immunity, leading to a complex state of immune dysfunction, in which signs of immune depression and immune activation paradoxically coexist.1–3 Although functional immune cell deficiencies predispose CKD patients to infectious complications, persistent immune cell activation contributes to a state of chronic inflammation that is associated with increased cardiovascular disease (CVD) risk. CVD and infection are the leading causes of morbidity and mortality in CKD.1–7 Hence, the immune dysfunction that accompanies CKD represents a major target for therapeutic interventions aiming to improve outcome.

Physical exercise has the potential to be one such therapy. It has been suggested that regular participation in moderate-intensity exercise may enhance certain aspects of immune function and exert anti-inflammatory effects.8–13 These effects are believed to contribute, at least in part, to the lower risk of infection and CVD that is observed in physically active individuals compared with their sedentary counterparts.12,13

Although the potential anti-inflammatory effects of regular exercise in CKD patients have been recognized, research in this area is lacking, particularly in predialysis patients.14,15 Apart from the potential benefits, given that exercise is currently advocated in the routine clinical care of CKD patients,16,17 it is also paramount to determine if exercise is safe to their underlying compromised immunity and inflammatory status. Although an acute bout of moderate exercise usually exerts little influence on immune and inflammatory responses in healthy people,18,19 it is not clear what effect it may have in CKD patients. Here, we report the separate effects of acute and regular moderate-intensity aerobic exercise on measures of immunity and systemic inflammation in predialysis CKD.

Results

Effects of Acute Exercise

Fifteen predialysis patients (Table 1) walked for 30 minutes on a motorized treadmill at a 1% gradient and a speed that elicited a rating of perceived exertion (RPE) in the range of 12–14 (somewhat hard). The effects of this acute bout of exercise on immune and inflammatory parameters are summarized in Table 2.

View this table:
  • View inline
  • View popup
Table 1.

Effect of acute exercise: patients’ characteristics

View this table:
  • View inline
  • View popup
Table 2.

Effects of acute exercise on immune and inflammatory parameters

Exercise induced an increase in total leukocyte concentration, which was more pronounced postexercise (P<0.001, effect size [ES]=0.44) but still observable at 1 hour postexercise (P=0.01, ES=0.27). These effects were mainly attributable to circulating neutrophils and lymphocytes, because exercise had no effect on monocyte count. Neutrophil concentration was elevated above pre-exercise levels postexercise (P<0.001, ES=0.35) and to a greater extent, 1 hour postexercise (P=0.002, ES=0.47). Lymphocyte concentration was also elevated postexercise (P<0.01, ES=0.53) but returned to pre-exercise levels by 1 hour postexercise.

Plasma elastase concentration (unstimulated neutrophil elastase release) was elevated above pre-exercise levels postexercise (P=0.03, ES=0.73) but returned to pre-exercise levels by 1 hour postexercise. Total neutrophil elastase release after 1 hour of in vitro stimulation with bacterial extract showed a trend to elevation postexercise (P=0.05, ES=0.22), which was evident at 1 hour postexercise (P<0.01, ES=0.54). When these data were expressed as bacterially-stimulated elastase release per neutrophil, values were also elevated in response to exercise; however, this result was only observed at 1 hour postexercise (P=0.04, ES=0.41).

There were no effects of exercise on the percentages of CD4+ or CD8++ lymphocytes expressing CD69 after 20 hours of in vitro staphylococcal enterotoxin B (SEB) stimulation or the SEB-stimulated CD69 expression by either CD4+CD69+ or CD8++CD69+ lymphocytes. Likewise, CD86 and HLA-DR expressions by SEB-stimulated CD14+CD86+HLA-DR+ monocytes were also unaffected.

Exercise induced an increase in plasma IL-6 levels, which was more evident postexercise (P<0.001, ES=0.33) but still noticeable at 1 hour postexercise (P=0.004, ES=0.25). Plasma IL-10 concentration was also elevated in response to acute exercise, and although an increase was already apparent postexercise (P<0.01, ES=0.58), it was further increased 1 hour postexercise (P=0.001, ES=1.12). Exercise also induced an elevation in plasma soluble TNF-receptor II (sTNF-RII) levels, which was only evident 1 hour postexercise (P=0.03, ES=0.30). Exercise had no effect on plasma soluble TNF-receptor I (sTNF-RI) and C-reactive protein (CRP) concentrations. The exercise-induced relative changes in these plasma markers of systemic inflammation are further illustrated in Supplemental Material (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Effects of regular exercise on expression of SEB-stimulated immune cell activation markers. Relative changes over 6 months in SEB-stimulated CD69 expression by CD4+CD69+ or CD8+CD69+ lymphocytes (left panel) and SEB-stimulated CD86 or HLA-DR expression by CD14+CD86+HLA-DR+ monocytes (right panel) for the exercise (white bars) and control (black bars) groups. Data are mean±SEM (n=13 exercise group; n=11 control group). GMFI, geometric mean of fluorescence intensity.

Effects of Regular Exercise

The effects of regular exercise were investigated in a previously documented study.20 Briefly, 20 patients were assigned to a 6-month home-based walking exercise program, whereas 20 other patients continued with their habitual physical activity (control group); of these patients, 18 exercisers and 14 controls completed the study. However, given the outcomes addressed here, we have excluded patients on immunosuppressive therapy, which left data from 13 exercisers and 11 controls; their baseline characteristics are shown in Table 3.

View this table:
  • View inline
  • View popup
Table 3.

Effects of regular exercise: patients’ baseline characteristics

We have previously reported that the exercise intervention improved exercise tolerance in the exercise group only.20 Data from the immune and inflammatory parameters investigated at baseline and 6 months for each group are summarized in Table 4. Most of the variables assessed did not differ between groups at baseline. Exceptions were CD86 expression by SEB-stimulated CD14+CD86+HLA-DR+ monocytes and plasma sTNF-RI levels (higher in exercisers) and CD69 expression by SEB-stimulated CD4+CD69+ and CD8++CD69+ lymphocytes (tendency to be higher in exercisers).

View this table:
  • View inline
  • View popup
Table 4.

Effects of regular exercise on immune and inflammatory parameters

There were no effects of the exercise intervention on total and differential blood leukocyte counts or measures of neutrophil degranulation. The percentages of SEB-stimulated CD4+ and CD8++ lymphocytes expressing CD69 were also unaffected by the exercise intervention. However, CD69 expression by SEB-stimulated CD4+CD69+ and CD8++CD69+ lymphocytes was downregulated after 6 months in exercisers (P=0.02, ES=0.59 and P=0.01, ES=0.65, respectively), whereas it remained unaltered in controls (P=0.91 and P=0.27, respectively). Likewise, the expression of CD86 and HLA-DR by SEB-stimulated CD14+CD86+HLA-DR+ monocytes was also downregulated after 6 months in exercisers (P=0.004, ES=1.27 and P=0.04, ES=0.72) but upregulated in controls (P=0.02, ES=0.76 and P=0.04, ES=0.51). Comparisons of the relative changes over 6 months between groups confirmed these effects (Figure 1).

Circulating IL-6 levels tended to be reduced (P=0.06, ES=0.40), and IL-10 levels tended to be increased (P=0.07, ES=0.66) in exercisers but remained unchanged in controls (P=0.43 and P=0.33, respectively). Consequently, the plasma IL-6/IL-10 ratio, reflecting overall inflammatory status, was reduced in exercisers, whereas it did not change in controls (Figure 2). Plasma sTNF-RI levels were also reduced (P=0.04, ES=0.20), and plasma sTNF-RII showed a tendency to reduction (P=0.06, ES=0.25) in exercisers but not controls (P=0.13 and P=0.50, respectively). In contrast, plasma CRP levels were unaffected by the exercise intervention.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Effects of regular exercise on plasma IL-6 to IL-10 ratio at baseline and 6 months for each group. Data are individual values (n=13 exercise group; n=11 control group). Time×group interaction: P=0.001.

There were no effects of the exercise intervention on body weight, renal function, proteinuria, or BP (Table 5).

View this table:
  • View inline
  • View popup
Table 5.

Effects of regular exercise on clinical parameters

Discussion

The impact of physical exercise on immunity and inflammation in predialysis CKD patients is unresolved. Previous research in this area is limited and has produced conflicting results, with one study reporting favorable effects of resistance exercise training21 and two other studies showing no effects of aerobic exercise training22,23 on plasma IL-6 and/or CRP levels. Here, we describe a more detailed examination of the impact of both acute and regular walking exercise on immunity and inflammation in CKD.

Effects of Acute Exercise

The main findings were that exercise enhanced neutrophil responsiveness to a bacterial challenge without affecting T-lymphocyte and monocyte activation and induced a systemic anti-inflammatory environment.

The observed effects of exercise on blood leukocyte counts were comparable with the effects usually reported in healthy individuals.19,24–26 As consistently reported,19,27 plasma elastase concentration was elevated immediately after exercise, indicating spontaneous neutrophil activation (degranulation in vivo) with return to resting levels within 1 hour. Considering that neutrophils are primed in CKD,28 this observation is particularly important, because it suggests that the exercise-induced neutrophil activation was only transient. Bacterially-stimulated elastase release per neutrophil was unaltered immediately after exercise but increased 1 hour later, indicating enhanced neutrophil responsiveness to a bacterial challenge in the postexercise period. This finding is in contrast to the reported reductions in stimulated neutrophil degranulation after numerous exercise protocols.19,27 Given that neutrophil dysfunction is believed to increase susceptibility to infection in CKD,29,30 a potential protective effect in the postexercise period is encouraging.

T lymphocytes and monocytes exhibit signs of both functional depression and activation in CKD.2,3 Importantly, our study suggests that acute exercise does not hinder T-lymphocyte and monocyte immune competence, and it does not aggravate their preactivated state.

It has been consistently reported that plasma IL-6 levels increase during exercise, with a magnitude that is determined by the combination of mode, intensity, and duration of the exercise performed.31,32 In CKD, circulating IL-6 levels are chronically elevated,33 raising a question about the safety of another exercise-induced increase. However, it is now clear that contracting skeletal muscle is the main source of the IL-6 in circulation in response to exercise,34,35 and muscle-derived IL-6, the first so-called myokine described,36 seems to mediate metabolic and anti-inflammatory effects both locally and systemically in an hormone-like fashion.8,32 In contrast to the cytokine cascade in sepsis, where IL-6 appearance is preceded by proinflammatory TNF-α and IL-1β, in response to exercise, IL-6 is typically the first cytokine present in the circulation, and then, it is followed by the cytokine inhibitors IL-1ra and sTNF-R as well as the anti-inflammatory IL-10.8,32 The kinetics of the cytokine response to exercise reported here are consistent with this finding. The greatest increase in IL-6 observed immediately after exercise was followed by a marked increase in IL-10 1 hour later, with a small increase in sTNF-RII also detected at this time. However, CRP was unaffected by exercise, which is expected, because alterations in CRP are often not seen until a few hours or even the day after exercise.37,38

In summary, a single bout of walking exercise in predialysis CKD patients seems to be safe from an immune and inflammatory perspective, improves immunosurveillance, and exerts anti-inflammatory effects.

Effects of Regular Exercise

The main findings of this study were that regular exercise downregulated T-lymphocyte and monocyte activation and that these effects were accompanied by improvements in systemic inflammation.

The exercise intervention had no effect on in vivo or in vitro neutrophil degranulation responses. In CKD, plasma elastase levels are elevated,39–41 and primed neutrophils are associated with inflammation and oxidative stress.28 Our findings indicate that regular exercise does not exacerbate the activation state of resting neutrophils (although transient spontaneous neutrophil activation occurs during each exercise bout). In addition, although the improved neutrophil responses observed after acute exercise do not translate into a chronic adaptation, given that neutrophil deficiencies may contribute to the high incidence of infections in CKD,30 it is reassuring that regular exercise does not hinder neutrophil immune competence. Furthermore, it is still possible that there is a window of protection after each exercise bout.

The observation that regular exercise downregulated T-lymphocyte activation is a very promising effect considering that it has been consistently shown that T lymphocytes are chronically activated in CKD.42–45 Given that T-lymphocyte preactivation in CKD patients is associated with premature apoptosis and impaired proliferation of these cells,43,44,46–48 it may be speculated that the observed decrease in T-lymphocyte activation might lead to enhanced function of these cells. Interestingly, previous studies in CKD have used sTNF-RI levels as an indicator of the susceptibility of T cells to undergo increased activation-induced cell death.44,48 Here, plasma sTNF-RI levels were reduced in exercisers but unaltered in controls, suggesting, albeit indirectly, that a downregulation of T-lymphocyte activation might have been accompanied by reduced T-lymphocyte apoptosis.

The exercise intervention also downregulated monocyte activation, and it is likely that it has contributed, at least in part, to the observed effects on T-lymphocyte activation, because it occurs through interactions between the monocyte and the T cell. However, given that exercise training downregulates monocyte Toll-like receptor 4 (TLR4) expression49,50 and that activation of TLRs upregulates monocyte expression of HLA-DR and CD86,51 it is plausible that the downregulation of CD86 and HLA-DR observed here was mediated by a downregulation of TLR4. Another explanation might be a reduced proportion of circulating CD16+ monocytes, which are known to express higher levels of CD86 and HLA-DR compared with classic monocytes51 and have been shown to be reduced after regular exercise.52 Interestingly, IL-10 production is low to absent in CD16+ monocytes.53 Although we did not perform direct measurements of monocyte IL-10 production, we did observe a trend for increased systemic IL-10 levels, which provides indirect support for a possible shift into a subset of circulating monocytes that are able to produce IL-10.

It may be argued that the observed reductions in T-lymphocyte and monocyte activation are signs of a detrimental effect of regular exercise on the orchestration of the adaptive immune response. However, it is important to recall that the complex state of immune dysfunction that accompanies CKD is characterized by immune depression as well as immune activation. Monocytes from CKD patients are preactivated and overproduce proinflammatory cytokines.54–58 Likewise, T lymphocytes from CKD patients show increased expression of early activation markers and heightened apoptotic turnover.43–48,59–61 Of note, data from our control patients indicates a progressive state of monocyte activation over the study period. Thus, it seems that the apparent exercise-induced downregulation of the immune response might be a small price to pay for the anti-inflammatory effects. Other than contributing to reduced inflammation, a downregulation of the preactivated state of immune cells might actually contribute to improved immune response in the longer term.3

The potential systemic anti-inflammatory effects of regular exercise were confirmed. In exercisers, plasma IL-6 concentration tended to be reduced after 6 months, whereas plasma IL-10 concentration tended to be increased, resulting in a significantly decreased ratio of IL-6 to IL-10 in the circulation. Plasma IL-6 levels are elevated and have consistently been shown to predict all-cause and cardiovascular mortality in CKD.33,62,63 Plasma levels of IL-10, one of the most important anti-inflammatory immune-regulating cytokines,64 are usually elevated in CKD because of persistent underlying inflammation.44,56,58 Hemodialysis patients with lower plasma IL-10 levels seem to be at greater risk for atherosclerosis,65 whereas those patients genetically predisposed to produce higher IL-10 levels show better immune balance66 and are at lower risk of cardiovascular events.67 It can be argued that the balance between IL-6 and IL-10 is a more valid parameter to draw conclusions about the overall inflammatory status. sTNF-Rs are the extracellular forms of the naturally occurring inhibitors of TNF but also, footprints of its activity68 and thus, not surprisingly elevated in CKD.42,48,69 Plasma sTNF-RI and sTNF-RII levels were or tended to be reduced after exercise, again suggesting an anti-inflammatory role of regular exercise in predialysis CKD patients.

In contrast to the favorable effects on plasma cytokines, we have failed to detect an effect of regular exercise on plasma CRP. This finding might be partly explained by the lack of an effect of the exercise intervention on body weight, because exercise without weight loss does not seem to reduce CRP.70 However, although it is also well established that CRP levels are elevated and predict all-cause and cardiovascular mortality in CKD,71,72 CRP is a rather nonspecific marker, and therefore, it might be difficult to detect changes in small patient cohorts. It is noteworthy that IL-6 has been consistently reported to be a stronger predictor of all-cause and cardiovascular outcomes in CKD than any other inflammatory marker, including CRP.63,73–77

In summary, our findings suggest that regular walking exercise in predialysis CKD patients is safe from immune and inflammatory perspectives and that it exerts anti-inflammatory effects at both systemic and cellular levels. Obviously, this study is limited by its small sample size, and such effects need to be confirmed in larger cohorts of predialysis CKD patients. In addition, given the close links between wasting, inflammation, and atherosclerosis in CKD,62,78 future studies should also address the impact of resistance exercise. There is initial evidence that regular resistance exercise can also induce anti-inflammatory effects in predialysis CKD patients,21 but a more in-depth study of such effects is warranted. Ideally, investigating both exercise modes alone and combined in representative groups of patients at different CKD stages would help tailor future exercise guidelines for this population.

In conclusion, this report provides convincing evidence that exercise has the potential to be an effective anti-inflammatory therapy in predialysis CKD patients and in this way, may reduce the high risk of CVD in these very vulnerable patients. Additional research is, however, needed to fully elucidate the impact of exercise on the complex state of immune dysfunction that accompanies CKD.

Concise Methods

Patients

Patients included in this report are subgroups of those patients described previously.20 All patients were recruited from nephrology outpatient clinics at Leicester General Hospital. Exclusion criteria were age<18 years, pregnancy, and orthopedic or cardiovascular disability that severely limited exercise capacity. The study received approval from the UK National Research Ethics Committee, and all patients gave written informed consent to participate.

The effects of acute exercise were investigated in a subgroup of patients that completed the baseline exercise test but were not receiving immunosuppressive therapy. The effects of regular exercise were investigated in a subgroup of patients that completed the 6-month study period but were not receiving immunosuppressive therapy. Patient characteristics are presented in Results (Tables 1 and 3).

Exercise Testing

All patients completed an exercise test at baseline and 6 months. At baseline, the exercise test consisted of 30 minutes of walking on a motorized treadmill at a 1% gradient and a speed that elicited an RPE in the range of 12–14 (somewhat hard).79 RPE was recorded every 2 minutes, and the treadmill speed was adjusted to maintain the RPE in the target range. The treadmill speed was also recorded every 2 minutes. At 6 months, the exercise test was repeated using exactly the same treadmill speed profile (i.e., same absolute exercise intensity), and the RPE response was recorded every 2 minutes. The effects of the exercise intervention on exercise tolerance have been previously reported.20

Exercise Program

Patients in the exercise group were prescribed a home-based exercise program, which consisted of at least 30 minutes of walking five times per week at an RPE in the range of 12–14 (somewhat hard) for a total duration of 6 months. Because most CKD patients receive β-blocker therapy, an overall heart rate (HR) range could not be used to prescribe the exercise intensity. Nevertheless, an individual HR range was established during the baseline exercise test by recording the HR response at the required RPE target range, and it was also provided to each patient in conjunction with an HR monitor. For monitoring purposes, patients were asked to keep exercise diaries, where they recorded the duration and the overall RPE of each exercise session. In addition, patients were requested to attend the hospital gym one time per month for a supervised exercise session to ensure compliance and make any necessary adjustments to the exercise program. Patients in the control group continued with their usual physical activity.

Blood Sampling, Handling, and Analysis

To investigate the effects of acute exercise, venous blood samples were obtained at rest (pre-exercise) and immediately after (postexercise) and 1 hour after (1 hour postexercise) the baseline exercise test. To investigate the effects of regular exercise, resting venous blood samples were obtained at baseline and 6 months. On both occasions, samples were collected at the same time of day, and patients were asked to refrain from exercise during the preceding 24 hours. All samples, approximately 20 ml each, were collected by venepuncture from an antecubital vein using a 21-g butterfly needle cannula and a dry syringe and immediately dispensed into two separate tubes as follows: approximately 7.5 ml into one S-Monovette tube (Sarstedt) containing K3EDTA (1.6 mg/ml) and approximately 12.5 ml into one universal tube containing heparin (16 units/ml).

Hematology

For the following analysis, K3EDTA-treated whole blood was used. Hemoglobin concentration was determined in duplicate using the cyanmethemoglobin method. Hematocrit was determined by measuring packed cell volumes in triplicate on a microhematocrit centrifuge. Plasma volume of resting blood samples was estimated from the hematocrit values. Plasma volume changes in postexercise blood samples were estimated from the hemoglobin and hematocrit values,80 and all cell counts and plasma measurements were corrected for these changes relative to the resting blood sample in the acute study only. In the exercise training study, there was no effect of time (baseline versus 6 months) on plasma volume (data not shown), and therefore, no adjustments were made. Total and differential leukocyte counts were determined using an automated hematology analyzer (Coulter Ac·T 5diff OV; Beckman Coulter).

Plasma Markers of Systemic Inflammation

The remaining K3EDTA-treated whole blood was centrifuged at 1500×g for 10 minutes in a refrigerated centrifuge at 4°C. The plasma obtained was aliquoted into Eppendorf tubes at 0.5 ml/tube and stored at −80°C for later determination of plasma concentrations of IL-6, IL-10, sTNF-RI, sTNF-RII, and CRP by ELISA as detailed in Supplemental Material.

Neutrophil Degranulation

One milliliter heparinized whole blood was immediately added to an Eppendorf tube containing 50 µl 10 mg/ml bacterial extract solution (stimulant, 84015; Sigma-Aldrich). The tube was sealed; blood and stimulant were mixed by gentle inversion, incubated for 1 hour at 37°C, and gently mixed again after 30 minutes. After incubation, the mixture was centrifuged for 2 minutes at 12,400×g, and the resulting supernatant was stored at −80°C before analysis. Another 1 ml heparinized whole blood was centrifuged at 1500×g for 10 minutes in a refrigerated centrifuge at 4°C, and the plasma obtained was stored at −80°C before analysis. Polymorphonuclear cell elastase concentration was determined in both bacterially stimulated and unstimulated (plasma elastase) samples using a commercially available ELISA kit (RD191021100; BioVendor GmbH) according to the manufacturer’s instructions. Bacterially stimulated and unstimulated samples were prediluted 1:1000 and 1:50 in the dilution buffer provided, respectively. All samples were assayed in duplicate, and all samples from the same patient were assayed in the same plate. The inter- and intra-assay coefficients of variation for all elastase ELISAs were 2.3% and 2.9%, respectively. Total bacterially-stimulated elastase release was calculated by subtracting plasma elastase concentration from the bacterially-stimulated elastase concentration and then, dividing by the neutrophil count to obtain the bacterially-stimulated elastase release per neutrophil.

T-Lymphocyte and Monocyte Activation

Two hundred-microliter aliquots of heparinized whole blood were cultured in 12×75-mm polystyrene round-bottomed tubes with caps (BD Biosciences) with no additive (unstimulated condition) or 1 µg/ml SEB (S4881; Sigma-Aldrich). Triplicate tubes were set up for each condition and incubated at 37°C in a humid 5% CO2 atmosphere for 20 hours. After incubation, the whole-blood aliquots were labeled in the respective culture tubes with cocktails of fluorochrome-conjugated mouse mAbs against human cell surface markers (BD Biosciences) as follows (one per condition): (1) lymphocyte surface markers: FITC-conjugated anti-CD4 (555346), phycoerythrin (PE)-conjugated anti-CD69 (555531), and PE-Cy5–conjugated anti-CD8 (555368); and (2) monocyte surface markers: FITC-conjugated anti-CD14 (555397), PE-conjugated anti-CD86 (555658), and peridinin–chlorophyll protein complex–conjugated anti–HLA-DR (347402). The remaining tube was left unstained. Labeling was carried out on ice for 20 minutes, which was followed by erythrocyte lysis and leukocyte fixation achieved by incubating samples for 10 minutes in the dark with FACS Lysing solution (BD Biosciences). Leukocytes were subsequently washed two times in PBS containing 0.1% BSA and 2 mM EDTA and resuspended again in the same buffer for immediate flow cytometer acquisition. Samples were acquired on a flow cytometer (BD FACSCalibur) equipped with the CellQuest software package (BD Biosciences). For samples labeled with lymphocyte markers, side scatter versus forward scatter plots were used to gate on the lymphocyte population by morphology, and 30,000 lymphocytes were acquired per sample. For samples labeled with monocyte markers, 100,000 total cells were acquired per sample. Negative unstained control samples were also acquired. Software-generated data files were stored for later analyses using FlowJo version 9 for Macintosh (Treestar) as detailed in Supplemental Material.

Statistical Analyses

Data are presented as mean±SD unless otherwise stated. All data were inspected for normality using the Shapiro–Wilk test. If a dataset was not normally distributed, statistical analysis was performed on the logarithmic transformation of the data, but data were back-transformed for presentation.

Data from the acute effects of exercise were examined using a one-factor (time: pre-exercise, postexercise, or 1 hour postexercise) ANOVA with repeated measures design. For any significant unadjusted F values subsequently shown, sphericity of the data was determined using the Mauchly’s test, and appropriate adjustments in the degrees of freedom were made81 (i.e., Greenhouse–Geisser correction was applied when Greenhouse–Geisser ε was <0.75 or Huynh–Feldt correction was used for less severe asphericity). A priori planned paired t tests with Holm–Bonferroni correction for multiple comparisons applied to the unadjusted P value were then performed between specific time points (postexercise versus pre-exercise and 1 hour postexercise versus pre-exercise).

To investigate the effects of regular exercise, baseline data were initially screened using independent t tests (exercise versus control). All data were then examined using an ANOVA with mixed design: within subjects (time: baseline versus 6 months)×between subjects (group: exercise versus control). Assumption of homogeneity was checked using Levene’s test. Where significant time×group interactions were observed, data were further examined using a priori planned t tests with Holm–Bonferroni correction as follows: paired (baseline versus 6 months) for each group and independent (exercise versus control) for 6-month data. T-lymphocyte and monocyte activation data were further examined by computing the relative (percentage of difference from baseline) changes over 6 months for each group and using independent t tests (exercise versus control).

Effect sizes were calculated according to Cohen82 with correction for sample size.83 Statistical significance was accepted at P<0.05.

Disclosures

None.

Acknowledgments

We thank Dr. Stephen John of Royal Derby Hospital for his assistance with the BP measurements in this study.

This work was partly supported by Kidney Research UK Grant RP33/1/2007 and Portuguese Foundation for Science and Technology Grant SFRH/BD/27838/2006. At the time of writing, J.L.V. was supported by the National Institute for Health Research Diet, Lifestyle & Physical Activity Biomedical Research Unit based at University Hospitals of Leicester and Loughborough University.

The views expressed are those of the authors and not necessarily the views of the NHS, the National Institute for Health Research, or the Department of Health.

Footnotes

  • N.C.B. and A.C.S. contributed equally to this work.

  • Published online ahead of print. Publication date available at www.jasn.org.

  • This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2013070702/-/DCSupplemental.

  • Copyright © 2014 by the American Society of Nephrology

References

  1. ↵
    1. Descamps-Latscha B,
    2. Jungers P,
    3. Witko-Sarsat V
    : Immune system dysregulation in uremia: Role of oxidative stress. Blood Purif 20: 481–484, 2002pmid:12207098
    OpenUrlCrossRefPubMedGoogle Scholar
  2. ↵
    1. Eleftheriadis T,
    2. Antoniadi G,
    3. Liakopoulos V,
    4. Kartsios C,
    5. Stefanidis I
    : Disturbances of acquired immunity in hemodialysis patients. Semin Dial 20: 440–451, 2007pmid:17897251
    OpenUrlCrossRefPubMedGoogle Scholar
  3. ↵
    1. Kato S,
    2. Chmielewski M,
    3. Honda H,
    4. Pecoits-Filho R,
    5. Matsuo S,
    6. Yuzawa Y,
    7. Tranaeus A,
    8. Stenvinkel P,
    9. Lindholm B
    : Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3: 1526–1533, 2008pmid:18701615
    OpenUrlAbstract/FREE Full TextGoogle Scholar
    1. Naqvi SB,
    2. Collins AJ
    : Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 13: 199–204, 2006pmid:16815225
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Saran AM,
    2. DuBose TD Jr.
    : Cardiovascular disease in chronic kidney disease. Ther Adv Cardiovasc Dis 2: 425–434, 2008pmid:19124439
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Dalrymple LS,
    2. Go AS
    : Epidemiology of acute infections among patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1487–1493, 2008pmid:18650409
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  4. ↵
    1. Stenvinkel P
    : Chronic kidney disease: A public health priority and harbinger of premature cardiovascular disease. J Intern Med 268: 456–467, 2010pmid:20809922
    OpenUrlCrossRefPubMedGoogle Scholar
  5. ↵
    1. Petersen AMW,
    2. Pedersen BK
    : The anti-inflammatory effect of exercise. J Appl Physiol (1985) 98: 1154–1162, 2005pmid:15772055
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Senchina DS,
    2. Kohut ML
    : Immunological outcomes of exercise in older adults. Clin Interv Aging 2: 3–16, 2007pmid:18044072
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Haaland DA,
    2. Sabljic TF,
    3. Baribeau DA,
    4. Mukovozov IM,
    5. Hart LE
    : Is regular exercise a friend or foe of the aging immune system? A systematic review. Clin J Sport Med 18: 539–548, 2008pmid:19001887
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Beavers KM,
    2. Brinkley TE,
    3. Nicklas BJ
    : Effect of exercise training on chronic inflammation. Clin Chim Acta 411: 785–793, 2010pmid:20188719
    OpenUrlCrossRefPubMedGoogle Scholar
  6. ↵
    1. Nieman D
    : Moderate exercise improves immunity and decreases illnesss rates. Am J Lifestyle Med 5: 338–345, 2011
    OpenUrlCrossRefGoogle Scholar
  7. ↵
    1. Gleeson M,
    2. Bishop NC,
    3. Stensel DJ,
    4. Lindley MR,
    5. Mastana SS,
    6. Nimmo MA
    : The anti-inflammatory effects of exercise: Mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol 11: 607–615, 2011pmid:21818123
    OpenUrlCrossRefPubMedGoogle Scholar
  8. ↵
    1. Bronas UG
    : Exercise training and reduction of cardiovascular disease risk factors in patients with chronic kidney disease. Adv Chronic Kidney Dis 16: 449–458, 2009pmid:19801135
    OpenUrlCrossRefPubMedGoogle Scholar
  9. ↵
    1. Heiwe S,
    2. Jacobson SH
    : Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 10: CD003236, 2011pmid:21975737
    OpenUrlPubMedGoogle Scholar
  10. ↵
    1. Kosmadakis GC,
    2. Bevington A,
    3. Smith AC,
    4. Clapp EL,
    5. Viana JL,
    6. Bishop NC,
    7. Feehally J
    : Physical exercise in patients with severe kidney disease. Nephron Clin Pract 115: c7–c16, 2010pmid:20173344
    OpenUrlCrossRefPubMedGoogle Scholar
  11. ↵
    1. Johansen KL,
    2. Painter P
    : Exercise in individuals with CKD. Am J Kidney Dis 59: 126–134, 2012pmid:22113127
    OpenUrlCrossRefPubMedGoogle Scholar
  12. ↵
    1. Gleeson M
    : Immune function in sport and exercise. J Appl Physiol (1985) 103: 693–699, 2007pmid:17303714
    OpenUrlCrossRefPubMedGoogle Scholar
  13. ↵
    1. Walsh NP,
    2. Gleeson M,
    3. Shephard RJ,
    4. Gleeson M,
    5. Woods JA,
    6. Bishop NC,
    7. Fleshner M,
    8. Green C,
    9. Pedersen BK,
    10. Hoffman-Goetz L,
    11. Rogers CJ,
    12. Northoff H,
    13. Abbasi A,
    14. Simon P
    : Position statement. Part one: Immune function and exercise. Exerc Immunol Rev 17: 6–63, 2011pmid:21446352
    OpenUrlPubMedGoogle Scholar
  14. ↵
    1. Kosmadakis GC,
    2. John SG,
    3. Clapp EL,
    4. Viana JL,
    5. Smith AC,
    6. Bishop NC,
    7. Bevington A,
    8. Owen PJ,
    9. McIntyre CW,
    10. Feehally J
    : Benefits of regular walking exercise in advanced pre-dialysis chronic kidney disease. Nephrol Dial Transplant 27: 997–1004, 2012pmid:21795756
    OpenUrlCrossRefPubMedGoogle Scholar
  15. ↵
    1. Castaneda C,
    2. Gordon PL,
    3. Parker RC,
    4. Uhlin KL,
    5. Roubenoff R,
    6. Levey AS
    : Resistance training to reduce the malnutrition-inflammation complex syndrome of chronic kidney disease. Am J Kidney Dis 43: 607–616, 2004pmid:15042537
    OpenUrlCrossRefPubMedGoogle Scholar
  16. ↵
    1. Leehey DJ,
    2. Moinuddin I,
    3. Bast JP,
    4. Qureshi S,
    5. Jelinek CS,
    6. Cooper C,
    7. Edwards LC,
    8. Smith BM,
    9. Collins EG
    : Aerobic exercise in obese diabetic patients with chronic kidney disease: A randomized and controlled pilot study. Cardiovasc Diabetol 8: 62, 2009pmid:20003224
    OpenUrlCrossRefPubMedGoogle Scholar
  17. ↵
    1. Headley S,
    2. Germain M,
    3. Milch C,
    4. Pescatello L,
    5. Coughlin MA,
    6. Nindl BC,
    7. Cornelius A,
    8. Sullivan S,
    9. Gregory S,
    10. Wood R
    : Exercise training improves HR responses and V˙O2peak in predialysis kidney patients. Med Sci Sports Exerc 44: 2392–2399, 2012pmid:22811032
    OpenUrlCrossRefPubMedGoogle Scholar
  18. ↵
    1. McCarthy DA,
    2. Grant M,
    3. Marbut M,
    4. Watling M,
    5. Wade AJ,
    6. Macdonald I,
    7. Nicholson S,
    8. Melsom RD,
    9. Perry JD
    : Brief exercise induces an immediate and a delayed leucocytosis. Br J Sports Med 25: 191–195, 1991pmid:1810612
    OpenUrlAbstract/FREE Full TextGoogle Scholar
    1. Nieman DC,
    2. Miller AR,
    3. Henson DA,
    4. Warren BJ,
    5. Gusewitch G,
    6. Johnson RL,
    7. Davis JM,
    8. Butterworth DE,
    9. Herring JL,
    10. Nehlsen-Cannarella SL
    : Effect of high- versus moderate-intensity exercise on lymphocyte subpopulations and proliferative response. Int J Sports Med 15: 199–206, 1994pmid:8063469
    OpenUrlCrossRefPubMedGoogle Scholar
  19. ↵
    1. Nieman DC,
    2. Henson DA,
    3. Austin MD,
    4. Brown VA
    : Immune response to a 30-minute walk. Med Sci Sports Exerc 37: 57–62, 2005pmid:15632669
    OpenUrlCrossRefPubMedGoogle Scholar
  20. ↵
    1. Peake JM
    : Exercise-induced alterations in neutrophil degranulation and respiratory burst activity: Possible mechanisms of action. Exerc Immunol Rev 8: 49–100, 2002pmid:12690938
    OpenUrlPubMedGoogle Scholar
  21. ↵
    1. Sela S,
    2. Shurtz-Swirski R,
    3. Cohen-Mazor M,
    4. Mazor R,
    5. Chezar J,
    6. Shapiro G,
    7. Hassan K,
    8. Shkolnik G,
    9. Geron R,
    10. Kristal B
    : Primed peripheral polymorphonuclear leukocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol 16: 2431–2438, 2005pmid:15987755
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  22. ↵
    1. Cohen G,
    2. Haag-Weber M,
    3. Hörl WH
    : Immune dysfunction in uremia. Kidney Int Suppl 62: S79–S82, 1997pmid:9350688
    OpenUrlPubMedGoogle Scholar
  23. ↵
    1. Chonchol M
    : Neutrophil dysfunction and infection risk in end-stage renal disease. Semin Dial 19: 291–296, 2006pmid:16893406
    OpenUrlCrossRefPubMedGoogle Scholar
  24. ↵
    1. Fischer CP
    : Interleukin-6 in acute exercise and training: What is the biological relevance? Exerc Immunol Rev 12: 6–33, 2006pmid:17201070
    OpenUrlPubMedGoogle Scholar
  25. ↵
    1. Pedersen BK,
    2. Febbraio MA
    : Muscle as an endocrine organ: Focus on muscle-derived interleukin-6. Physiol Rev 88: 1379–1406, 2008pmid:18923185
    OpenUrlCrossRefPubMedGoogle Scholar
  26. ↵
    1. Stenvinkel P,
    2. Ketteler M,
    3. Johnson RJ,
    4. Lindholm B,
    5. Pecoits-Filho R,
    6. Riella M,
    7. Heimbürger O,
    8. Cederholm T,
    9. Girndt M
    : IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney Int 67: 1216–1233, 2005pmid:15780075
    OpenUrlCrossRefPubMedGoogle Scholar
  27. ↵
    1. Steensberg A,
    2. van Hall G,
    3. Osada T,
    4. Sacchetti M,
    5. Saltin B,
    6. Klarlund Pedersen B
    : Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J Physiol 529: 237–242, 2000pmid:11080265
    OpenUrlCrossRefPubMedGoogle Scholar
  28. ↵
    1. Toft AD,
    2. Falahati A,
    3. Steensberg A
    : Source and kinetics of interleukin-6 in humans during exercise demonstrated by a minimally invasive model. Eur J Appl Physiol 111: 1351–1359, 2011pmid:21153418
    OpenUrlCrossRefPubMedGoogle Scholar
  29. ↵
    1. Pedersen BK,
    2. Steensberg A,
    3. Fischer C,
    4. Keller C,
    5. Keller P,
    6. Plomgaard P,
    7. Febbraio M,
    8. Saltin B
    : Searching for the exercise factor: Is IL-6 a candidate? J Muscle Res Cell Motil 24: 113–119, 2003pmid:14609022
    OpenUrlCrossRefPubMedGoogle Scholar
  30. ↵
    1. Kasapis C,
    2. Thompson PD
    : The effects of physical activity on serum C-reactive protein and inflammatory markers: A systematic review. J Am Coll Cardiol 45: 1563–1569, 2005pmid:15893167
    OpenUrlCrossRefPubMedGoogle Scholar
  31. ↵
    1. Plaisance EP,
    2. Grandjean PW
    : Physical activity and high-sensitivity C-reactive protein. Sports Med 36: 443–458, 2006pmid:16646631
    OpenUrlCrossRefPubMedGoogle Scholar
  32. ↵
    1. Costa E,
    2. Rocha S,
    3. Rocha-Pereira P,
    4. Nascimento H,
    5. Castro E,
    6. Miranda V,
    7. Faria MS,
    8. Loureiro A,
    9. Quintanilha A,
    10. Belo L,
    11. Santos-Silva A
    : Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 28: 935–940, 2008pmid:18587235
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Caimi G,
    2. Carollo C,
    3. Montana M,
    4. Vaccaro F,
    5. Lo Presti R
    : Elastase, myeloperoxidase, nitric oxide metabolites and oxidative status in subjects with clinical stable chronic renal failure on conservative treatment. Clin Hemorheol Microcirc 43: 253–258, 2009pmid:19847059
    OpenUrlPubMedGoogle Scholar
  33. ↵
    1. Polańska B,
    2. Augustyniak D,
    3. Makulska I,
    4. Niemczuk M,
    5. Zwolińska D,
    6. Jankowski A
    : Elastase, α1-proteinase inhibitor, and interleukin-8 in pre-dialyzed and hemodialyzed patients with chronic kidney disease. Pediatr Int 52: 735–743, 2010pmid:20487365
    OpenUrlCrossRefPubMedGoogle Scholar
  34. ↵
    1. Descamps-Latscha B,
    2. Herbelin A,
    3. Nguyen AT,
    4. Roux-Lombard P,
    5. Zingraff J,
    6. Moynot A,
    7. Verger C,
    8. Dahmane D,
    9. de Groote D,
    10. Jungers P
    ,: Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 154: 882–892, 1995pmid:7814891
    OpenUrlAbstractGoogle Scholar
  35. ↵
    1. Meier P,
    2. Dayer E,
    3. Blanc E,
    4. Wauters J-P
    : Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J Am Soc Nephrol 13: 204–212, 2002pmid:11752039
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  36. ↵
    1. Moser B,
    2. Roth G,
    3. Brunner M,
    4. Lilaj T,
    5. Deicher R,
    6. Wolner E,
    7. Kovarik J,
    8. Boltz-Nitulescu G,
    9. Vychytil A,
    10. Ankersmit HJ
    : Aberrant T cell activation and heightened apoptotic turnover in end-stage renal failure patients: A comparative evaluation between non-dialysis, haemodialysis, and peritoneal dialysis. Biochem Biophys Res Commun 308: 581–585, 2003pmid:12914790
    OpenUrlCrossRefPubMedGoogle Scholar
  37. ↵
    1. Litjens NHR,
    2. van Druningen CJ,
    3. Betjes MGH
    : Progressive loss of renal function is associated with activation and depletion of naive T lymphocytes. Clin Immunol 118: 83–91, 2006pmid:16257266
    OpenUrlCrossRefPubMedGoogle Scholar
  38. ↵
    1. Meier P,
    2. Dayer E,
    3. Ronco P,
    4. Blanc E
    : Dysregulation of IL-2/IL-2R system alters proliferation of early activated CD4+ T cell subset in patients with end-stage renal failure. Clin Nephrol 63: 8–21, 2005pmid:15678692
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Meier P,
    2. Spertini F,
    3. Blanc E,
    4. Burnier M
    : Oxidized low-density lipoproteins activate CD4+ T cell apoptosis in patients with end-stage renal disease through Fas engagement. J Am Soc Nephrol 18: 331–342, 2007pmid:17182885
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  39. ↵
    1. Ankersmit HJ,
    2. Deicher R,
    3. Moser B,
    4. Teufel I,
    5. Roth G,
    6. Gerlitz S,
    7. Itescu S,
    8. Wolner E,
    9. Boltz-Nitulescu G,
    10. Kovarik J
    : Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol 125: 142–148, 2001pmid:11472437
    OpenUrlCrossRefPubMedGoogle Scholar
  40. ↵
    1. Flynn MG,
    2. McFarlin BK
    : Toll-like receptor 4: Link to the anti-inflammatory effects of exercise? Exerc Sport Sci Rev 34: 176–181, 2006pmid:17031256
    OpenUrlCrossRefPubMedGoogle Scholar
  41. ↵
    1. Gleeson M,
    2. McFarlin B,
    3. Flynn M
    : Exercise and Toll-like receptors. Exerc Immunol Rev 12: 34–53, 2006pmid:17201071
    OpenUrlPubMedGoogle Scholar
  42. ↵
    1. Takeda K,
    2. Kaisho T,
    3. Akira S
    : Toll-like receptors. Annu Rev Immunol 21: 335–376, 2003pmid:12524386
    OpenUrlCrossRefPubMedGoogle Scholar
  43. ↵
    1. Timmerman KL,
    2. Flynn MG,
    3. Coen PM,
    4. Markofski MM,
    5. Pence BD
    : Exercise training-induced lowering of inflammatory (CD14+CD16+) monocytes: A role in the anti-inflammatory influence of exercise? J Leukoc Biol 84: 1271–1278, 2008pmid:18664531
    OpenUrlCrossRefPubMedGoogle Scholar
  44. ↵
    1. Ziegler-Heitbrock L
    : The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol 81: 584–592, 2007pmid:17135573
    OpenUrlCrossRefPubMedGoogle Scholar
  45. ↵
    1. Girndt M,
    2. Köhler H,
    3. Schiedhelm-Weick E,
    4. Schlaak JF,
    5. Meyer zum Büschenfelde KH,
    6. Fleischer B
    : Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 47: 559–565, 1995pmid:7723241
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Girndt M,
    2. Sester U,
    3. Kaul H,
    4. Köhler H
    : Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 9: 1689–1696, 1998pmid:9727378
    OpenUrlAbstractGoogle Scholar
  46. ↵
    1. Morita Y,
    2. Yamamura M,
    3. Kashihara N,
    4. Makino H
    : Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 98: 19–33, 1997pmid:9434312
    OpenUrlPubMedGoogle Scholar
    1. Higuchi T,
    2. Yamamoto C,
    3. Kuno T,
    4. Mizuno M,
    5. Takahashi S,
    6. Kanmatsuse K
    : Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron 76: 26–31, 1997pmid:9171296
    OpenUrlCrossRefPubMedGoogle Scholar
  47. ↵
    1. Sardenberg C,
    2. Suassuna P,
    3. Watanabe R,
    4. Cruz Andreoli MC,
    5. Aparecida Dalboni M,
    6. Faria Seabra V,
    7. Draibe SA,
    8. Cendoroglo Neto M,
    9. Jaber B
    : Balance between cytokine production by peripheral blood mononuclear cells and reactive oxygen species production by monocytes in patients with chronic kidney disease. Ren Fail 26: 673–681, 2004pmid:15600259
    OpenUrlCrossRefPubMedGoogle Scholar
  48. ↵
    1. Meier P,
    2. Meier R,
    3. Blanc E
    : Influence of CD4+/CD25+ regulatory T cells on atherogenesis in patients with end-stage kidney disease. Expert Rev Cardiovasc Ther 6: 987–997, 2008pmid:18666849
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Meier P,
    2. von Fliedner V,
    3. Markert M,
    4. van Melle G,
    5. Deppisch R,
    6. Wauters JP
    : One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients. Blood Purif 18: 128–137, 2000pmid:10838472
    OpenUrlCrossRefPubMedGoogle Scholar
  49. ↵
    1. Stachowski J,
    2. Pollok M,
    3. Burrichter H,
    4. Baldamus CA
    : Immunodeficiency in ESRD-patients is linked to altered IL-2 receptor density on T cell subsets. J Clin Lab Immunol 34: 171–177, 1991pmid:1668284
    OpenUrlPubMedGoogle Scholar
  50. ↵
    1. Stenvinkel P,
    2. Bárány P,
    3. Heimbürger O,
    4. Pecoits-Filho R,
    5. Lindholm B
    : Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int Suppl 80: 103–108, 2002pmid:11982823
    OpenUrlPubMedGoogle Scholar
  51. ↵
    1. Barreto DV,
    2. Barreto FC,
    3. Liabeuf S,
    4. Temmar M,
    5. Lemke H-D,
    6. Tribouilloy C,
    7. Choukroun G,
    8. Vanholder R,
    9. Massy ZA,
    10. European Uremic Toxin Work Group (EUTox)
    : Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77: 550–556, 2010pmid:20016471
    OpenUrlCrossRefPubMedGoogle Scholar
  52. ↵
    1. Moore KW,
    2. de Waal Malefyt R,
    3. Coffman RL,
    4. O’Garra A
    : Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683–765, 2001pmid:11244051
    OpenUrlCrossRefPubMedGoogle Scholar
  53. ↵
    1. Seyrek N,
    2. Karayaylali I,
    3. Balal M,
    4. Paydas S,
    5. Aikimbaev K,
    6. Cetiner S,
    7. Seydaoglu G
    : Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients? Scand J Urol Nephrol 39: 405–409, 2005pmid:16257843
    OpenUrlCrossRefPubMedGoogle Scholar
  54. ↵
    1. Girndt M,
    2. Sester U,
    3. Sester M,
    4. Deman E,
    5. Ulrich C,
    6. Kaul H,
    7. Köhler H
    : The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients. Kidney Int 60: 2385–2391, 2001pmid:11737614
    OpenUrlCrossRefPubMedGoogle Scholar
  55. ↵
    1. Girndt M,
    2. Kaul H,
    3. Sester U,
    4. Ulrich C,
    5. Sester M,
    6. Georg T,
    7. Köhler H
    : Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int 62: 949–955, 2002pmid:12164877
    OpenUrlCrossRefPubMedGoogle Scholar
  56. ↵
    1. Brockhaus M
    : Soluble TNF receptor: What is the significance? Intensive Care Med 23: 808–809, 1997pmid:9310797
    OpenUrlCrossRefPubMedGoogle Scholar
  57. ↵
    1. Pereira BJ,
    2. Shapiro L,
    3. King AJ,
    4. Falagas ME,
    5. Strom JA,
    6. Dinarello CA
    : Plasma levels of IL-1 beta, TNF alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45: 890–896, 1994pmid:8196293
    OpenUrlCrossRefPubMedGoogle Scholar
  58. ↵
    1. Church TS,
    2. Earnest CP,
    3. Thompson AM,
    4. Priest EL,
    5. Rodarte RQ,
    6. Saunders T,
    7. Ross R,
    8. Blair SN
    : Exercise without weight loss does not reduce C-reactive protein: The INFLAME study. Med Sci Sports Exerc 42: 708–716, 2010pmid:19952828
    OpenUrlPubMedGoogle Scholar
  59. ↵
    1. Lacson E Jr,
    2. Levin NW
    : C-reactive protein and end-stage renal disease. Semin Dial 17: 438–448, 2004pmid:15660574
    OpenUrlCrossRefPubMedGoogle Scholar
  60. ↵
    1. Wanner C,
    2. Drechsler C,
    3. Krane V
    : C-reactive protein and uremia. Semin Dial 22: 438–441, 2009pmid:19708997
    OpenUrlCrossRefPubMedGoogle Scholar
  61. ↵
    1. Wetmore JB,
    2. Lovett DH,
    3. Hung AM,
    4. Cook-Wiens G,
    5. Mahnken JD,
    6. Sen S,
    7. Johansen KL
    : Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton) 13: 593–600, 2008pmid:18826487
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Pachaly MA,
    2. do Nascimento MM,
    3. Suliman ME,
    4. Hayashi SY,
    5. Riella MC,
    6. Manfro RC,
    7. Stenvinkel P,
    8. Lindholm B
    : Interleukin-6 is a better predictor of mortality as compared to C-reactive protein, homocysteine, pentosidine and advanced oxidation protein products in hemodialysis patients. Blood Purif 26: 204–210, 2008pmid:18285696
    OpenUrlCrossRefPubMedGoogle Scholar
    1. Zoccali C,
    2. Tripepi G,
    3. Mallamaci F
    : Dissecting inflammation in ESRD: Do cytokines and C-reactive protein have a complementary prognostic value for mortality in dialysis patients? J Am Soc Nephrol 17[Suppl 3]: S169–S173, 2006pmid:17130257
    OpenUrlAbstract/FREE Full TextGoogle Scholar
    1. Honda H,
    2. Qureshi AR,
    3. Heimbürger O,
    4. Bárány P,
    5. Wang K,
    6. Pecoits-Filho R,
    7. Stenvinkel P,
    8. Lindholm B
    : Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47: 139–148, 2006pmid:16377395
    OpenUrlCrossRefPubMedGoogle Scholar
  62. ↵
    1. Tripepi G,
    2. Mallamaci F,
    3. Zoccali C
    : Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: Searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 16[Suppl 1]: S83–S88, 2005pmid:15938042
    OpenUrlAbstract/FREE Full TextGoogle Scholar
  63. ↵
    1. Stenvinkel P,
    2. Heimbürger O,
    3. Paultre F,
    4. Diczfalusy U,
    5. Wang T,
    6. Berglund L,
    7. Jogestrand T
    : Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899–1911, 1999pmid:10231453
    OpenUrlCrossRefPubMedGoogle Scholar
  64. ↵
    1. Borg GA
    : Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14: 377–381, 1982pmid:7154893
    OpenUrlCrossRefPubMedGoogle Scholar
  65. ↵
    1. Dill DB,
    2. Costill DL
    : Calculation of percentage changes in volumes of blood, plasma, and red cells in dehydration. J Appl Physiol 37: 247–248, 1974pmid:4850854
    OpenUrlPubMedGoogle Scholar
  66. ↵
    1. Atkinson G
    : Analysis of repeated measurements in physical therapy research. Phys Ther Sport 2: 194–208, 2001
    OpenUrlCrossRefGoogle Scholar
  67. ↵
    1. Cohen JW
    : Statistical Power Analysis for the Behavioral Sciences, 2nd Ed., Hillsdale, NJ, Lawrence Erlbaum Associates, 1988
    Google Scholar
  68. ↵
    1. Hedges LV
    : Distributional theory for Glass’s estimator of effect size and related estimators. J Educ Stat 6: 107–128, 1981
    OpenUrlCrossRefGoogle Scholar
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 25 (9)
Journal of the American Society of Nephrology
Vol. 25, Issue 9
September 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Citation Tools
Request Permissions
Share
Evidence for Anti-Inflammatory Effects of Exercise in CKD
João L. Viana, George C. Kosmadakis, Emma L. Watson, Alan Bevington, John Feehally, Nicolette C. Bishop, Alice C. Smith
JASN Sep 2014, 25 (9) 2121-2130; DOI: 10.1681/ASN.2013070702
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Concise Methods
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • The Effect of Tolvaptan on BP in Polycystic Kidney Disease: A Post Hoc Analysis of the TEMPO 3:4 Trial
  • Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD
  • Exploring the Complexity of Death-Censored Kidney Allograft Failure
Show more Clinical Research

Cited By...

  • Establishment and characterisation of primary skeletal muscle cell cultures from patients with advanced Chronic Kidney Disease
  • The association of exercise and sedentary behaviours with incident end-stage renal disease: the Southern Community Cohort Study
  • Metabolic Effects of Diet and Exercise in Patients with Moderate to Severe CKD: A Randomized Clinical Trial
  • Participant acceptability of exercise in kidney disease (PACE-KD): a feasibility study protocol in renal transplant recipients
  • Physical activity, immune function and inflammation in kidney patients (the PINK study): a feasibility trial protocol
  • Misclassification of Obesity in CKD: Appearances Are Deceptive
  • Google Scholar

Similar Articles

  • Low Health Literacy is Associated with the Onset of CKD during the Life Course
  • Metabolic Effects of Diet and Exercise in Patients with Moderate to Severe CKD: A Randomized Clinical Trial
  • Hepatocyte Growth Factor–Secreting Mesothelial Cell Sheets Suppress Progressive Fibrosis in a Rat Model of CKD
  • Constipation and Incident CKD
  • IL-1 Inhibition and Vascular Function in CKD
See more

Related Articles

  • PubMed
  • Google Scholar

We recommend

  1. Aspects of Immune Dysfunction in End-stage Renal Disease
    Sawako Kato et al., Clin J Am Soc Nephrol, 2008
  2. IκB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD
    Jianmin Chen et al., J Am Soc Nephrol, 2016
  3. Neutrophil Serine Proteases Promote IL-1β Generation and Injury in Necrotizing Crescentic Glomerulonephritis
    Adrian Schreiber et al., J Am Soc Nephrol, 2012
  4. Immune-Regulatory Molecule CD69 Controls Peritoneal Fibrosis
    Laura García Ramírez et al., J Am Soc Nephrol, 2016
  1. The effects of different stimulators on the activation of human lymphocytes
    YAN Zheng et al., Acta Pharmaceutica Sinica, 2019
  2. Predictive value of immune cell counts and neutrophil-to-lymphocyte ratio for 28-day mortality in patients with sepsis caused by intra-abdominal infection
    Shuangqing Liu, Burns & Trauma, 2021
  3. Effect of indomethacin on immunity and coagulation state in patients with colon cancer recurrence/metastasis
    HU Zhi-qiu et al., Current Immunology, 2019
  4. Painless Chronic Pancreatitis Assiciated with Exocrine Insufficiency
    Endocrinology Advisor, 2020
Powered by
  • Privacy policy
  • Do not sell my personal information
  • Google Analytics settings
I consent to the use of Google Analytics and related cookies across the TrendMD network (widget, website, blog). Learn more

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2021 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire
Email this Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
Evidence for Anti-Inflammatory Effects of Exercise in CKD
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Evidence for Anti-Inflammatory Effects of Exercise in CKD
João L. Viana, George C. Kosmadakis, Emma L. Watson, Alan Bevington, John Feehally, Nicolette C. Bishop, Alice C. Smith
JASN Sep 2014, 25 (9) 2121-2130; DOI: 10.1681/ASN.2013070702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

PDFHelp